Валеология: Здоровье, Болезнь, Выздоровление. 2020; : 51-56
ТРАНСАРТЕРИАЛЬНАЯ ХИМИОЭМБОЛИЗАЦИЯ ПЕЧЕНОЧНЫХ АРТЕРИЙ. СОВРЕМЕННЫЕ ТЕНДЕНЦИИ РАЗВИТИЯ
Аннотация
Трансартериальная химиоэмболизация печеночной артерии (ХЭПА) является самым широко используемым методом локальнорегиональной терапии при гепатоцеллюлярной карциноме (ГЦК) не только на промежуточной стадии заболевания, но также зачастую на ранней и поздней стадиях. В обзоре описаны современные мировые тенденции развития технологии.
Список литературы
1. Показатели онкологической службы РК за 2018 г. – Алматы, 2019. – Статистический сборник. - 214 с.
2. Hansmann J., Ray C. E. Jr. Overview of Staging Systems for Hepatocellular Carcinoma and Implications for Interventional Radiology. Semin Intervent Radiol. 2017 Jun; 34 (2): 213-219.
3. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018 Jul; 69 (1): 182-236.
4. Omata M., Cheng A. L., Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017 Jul; 11 (4): 317-370.
5. Forner A., Reig M., Bruix J. Hepatocellular carcinoma. Lancet. 2018 Mar 31; 391 (10127): 1301-1314.
6. Galle P. R., Forner A., and all EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69: 182-236.
7. Llovet J. M., Real M. I., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet (London, England) 2002; 359: 1734–9.
8. Lo C.-M., Ngan H., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164–71.
9. Llovet J. M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429–42.
10. Camma C.,Schepis F., et. al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: metaanalysis of randomized controlled trials. Radiology 2002; 224: 47–54.
11. Bargellini I., Florio F., et al. Trends in utilization of transarterial treatments for hepatocellular carcinoma: results of a survey by the Italian Society of Interventional Radiology. Cardiovasc Intervent Radiol 2014; 37: 438–44.
12. Facciorusso A. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art. World J Gastroenterol 2018; 24: 161–9
13. Zhou J., Sun H., et al. Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). Liver Cancer 2018; 7: 235-60.
14. Fohlen A., Tasu J. P., et al. Transarterial chemoembolization (TACE) in the management of hepatocellular carcinoma: Results of a French national survey on current practices. Diagn Interv Imaging 2018; 99: 527–35.
15. Varela M., Real M. I. et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474–81.
16. Lammer J., Malagari K., et al. Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma : Results of the PRECISION V Study. Cardiovasc Intervent Radiol, 2010; 33: 41–52.
17. Golfieri R., Giampalma E., et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 2014; 111: 255–64.
18. Gao S., Yang Z. et al. Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology 2013; 60: 813–20.
19. Marelli L., Stigliano R., et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 6–25.
20. Lencioni R., de Baere T., et al. Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol 2012; 35: 980–5.
21. Boulin M., Hillon P., et al. Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial. Aliment Pharmacol Ther 2014; 39: 1301–13.
22. Watanabe S., Nishioka M., et al. Prospective and randomized controlled study of chemoembolization therapy in patients with advanced hepatocellular carcinoma. Cooperative Study Group for Liver Cancer Treatment in Shikoku area. Cancer Chemother Pharmacol 1994; 33 Suppl: S 93-6.
23. Vogl T. J., Lammer J., et al. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am J Roentgenol 2011; 197: W 562-70.
24. Vadot L., Boulin M., et.al. Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma. J Clin Pharm Ther 2015; 40: 83–90.
25. Cucchetti A., Trevisani F., et al. Costeffectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemoembolization for hepatocellular carcinoma. Dig Liver Dis 2016; 48: 798–805.
Valeology: Health - Illnes - recovery. 2020; : 51-56
TRANSTERTERIAL CHEMIOEMBOLIZATION OF THE HEPATIC ARTERIES. CURRENT DEVELOPMENT TRENDS
Abstract
Hepatic artery transarterial chemoembolization (HEPA) is the most widely used method of local regional therapy for hepatocellular carcinoma (HCC), not only in the intermediate stage of the disease, but also often in the early and late stages. The review describes current global trends
in the development of technology.
References
1. Pokazateli onkologicheskoi sluzhby RK za 2018 g. – Almaty, 2019. – Statisticheskii sbornik. - 214 s.
2. Hansmann J., Ray C. E. Jr. Overview of Staging Systems for Hepatocellular Carcinoma and Implications for Interventional Radiology. Semin Intervent Radiol. 2017 Jun; 34 (2): 213-219.
3. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018 Jul; 69 (1): 182-236.
4. Omata M., Cheng A. L., Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017 Jul; 11 (4): 317-370.
5. Forner A., Reig M., Bruix J. Hepatocellular carcinoma. Lancet. 2018 Mar 31; 391 (10127): 1301-1314.
6. Galle P. R., Forner A., and all EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69: 182-236.
7. Llovet J. M., Real M. I., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet (London, England) 2002; 359: 1734–9.
8. Lo C.-M., Ngan H., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164–71.
9. Llovet J. M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429–42.
10. Camma C.,Schepis F., et. al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: metaanalysis of randomized controlled trials. Radiology 2002; 224: 47–54.
11. Bargellini I., Florio F., et al. Trends in utilization of transarterial treatments for hepatocellular carcinoma: results of a survey by the Italian Society of Interventional Radiology. Cardiovasc Intervent Radiol 2014; 37: 438–44.
12. Facciorusso A. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art. World J Gastroenterol 2018; 24: 161–9
13. Zhou J., Sun H., et al. Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). Liver Cancer 2018; 7: 235-60.
14. Fohlen A., Tasu J. P., et al. Transarterial chemoembolization (TACE) in the management of hepatocellular carcinoma: Results of a French national survey on current practices. Diagn Interv Imaging 2018; 99: 527–35.
15. Varela M., Real M. I. et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474–81.
16. Lammer J., Malagari K., et al. Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma : Results of the PRECISION V Study. Cardiovasc Intervent Radiol, 2010; 33: 41–52.
17. Golfieri R., Giampalma E., et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 2014; 111: 255–64.
18. Gao S., Yang Z. et al. Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology 2013; 60: 813–20.
19. Marelli L., Stigliano R., et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 6–25.
20. Lencioni R., de Baere T., et al. Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol 2012; 35: 980–5.
21. Boulin M., Hillon P., et al. Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial. Aliment Pharmacol Ther 2014; 39: 1301–13.
22. Watanabe S., Nishioka M., et al. Prospective and randomized controlled study of chemoembolization therapy in patients with advanced hepatocellular carcinoma. Cooperative Study Group for Liver Cancer Treatment in Shikoku area. Cancer Chemother Pharmacol 1994; 33 Suppl: S 93-6.
23. Vogl T. J., Lammer J., et al. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am J Roentgenol 2011; 197: W 562-70.
24. Vadot L., Boulin M., et.al. Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma. J Clin Pharm Ther 2015; 40: 83–90.
25. Cucchetti A., Trevisani F., et al. Costeffectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemoembolization for hepatocellular carcinoma. Dig Liver Dis 2016; 48: 798–805.
